Organon & Co. (OGN) financials — revenue, cash, debt and margins

Key figures

Trailing twelve months where a flow is involved, latest reported balance where it is not.

Valuation

Market cap: $3.6B
P/E (TTM): 17.63
Price / sales: 0.59
EV / EBITDA: —
Price / book: 3.59

Cash flow

FCF yield: 15.7%
SBC-adjusted FCF yield: 13.6%
SBC impact: 13.2%
Stock compensation (TTM): $75M

Margins & growth

Profit margin: 3.4%
Operating margin: —
Quarterly revenue (year on year): -2.3%
Quarterly earnings (year on year): -25.5%

Balance sheet

Cash & investments: $1.1B
Debt: $8.6B
Net cash / (debt): -$7.4B

Where the revenue comes from

What this company sells, and where it sells it, as the filings break it down.

By product or service

Year to Dec 31, 2025 · $6B

Nexplanon Implanon NXT15%
$921M-4.4% vs. a year earlier
Zetia6%
$342M+7.9% vs. a year earlier
Other Sundry Established Brands6%
$338M+3.0% vs. a year earlier
Atozet5%
$324M-31.5% vs. a year earlier
Other Non Opiod Pain Bone and Dermatology5%
$301M+2.0% vs. a year earlier
Arcoxia4%
$265M-1.9% vs. a year earlier
Follistim AQ4%
$264M+11.4% vs. a year earlier
Nasonex4%
$262M-5.1% vs. a year earlier
Singulair4%
$252M-29.8% vs. a year earlier
Renflexis4%
$251M-8.4% vs. a year earlier
Hadlima4%
$228M+60.6% vs. a year earlier
Cozaar Hyzaar4%
$219M-9.9% vs. a year earlier
Other Womens Health3%
$174M+10.1% vs. a year earlier
Dulera3%
$153M-24.6% vs. a year earlier
Diprospan2%
$150M+7.9% vs. a year earlier
Fosamax2%
$143M-5.3% vs. a year earlier
Vtama2%
$128M+966.7% vs. a year earlier
Marvelon Mercilon2%
$127M-5.2% vs. a year earlier
Other Cardiovascular2%
$126M-5.3% vs. a year earlier
Clarinex2%
$123M-3.1% vs. a year earlier
Propecia2%
$118M+6.3% vs. a year earlier
Ganirelix Acetate Injection2%
$101M-7.3% vs. a year earlier
Vytorin2%
$100M-7.4% vs. a year earlier
Ontruzant2%
$99M-29.8% vs. a year earlier
Proscar2%
$97M+2.1% vs. a year earlier
Nuva Ring2%
$91M-20.9% vs. a year earlier
Other Sundry Products1%
$82M-28.7% vs. a year earlier
Brenzys1%
$80M+3.9% vs. a year earlier
Jada1%
$74M+21.3% vs. a year earlier
Other Respiratory1%
$52M-1.9% vs. a year earlier
Other Biosimilars1%
$33M+17.9% vs. a year earlier
Rosuzet0.40%
$24M-51.0% vs. a year earlier

These lines account for 97% of revenue. Each breakdown reconciles to the total by its own route, so they need not agree with one another.

By region

Year to Dec 31, 2025 · $6.2B

Europe and Canada26%
$1.6B-8.2% vs. a year earlier
United States26%
$1.6B+2.0% vs. a year earlier
Latin America Middle East Russia and Africa17%
$1.1B+3.7% vs. a year earlier
Asia Pacific and Japan16%
$1B-4.8% vs. a year earlier
China13%
$829M-2.1% vs. a year earlier
Other Countries1%
$93M-32.1% vs. a year earlier

What it owns and what it owes

Both on one scale, because both are money — the bar that is taller is the one that matters.

Cash and debt

Cash & InvestmentsTotal Debt

Cash counts short-term investments, not just the bank balance — technology companies park most of it in marketable securities, and leaving those out understates it several times over. Debt includes lease obligations.

Where the money goes

Cost of RevenueR&D ExpenseSG&A Expense

Only the three costs filers report consistently. Anything a company does not break out sits outside these bands, so the stack is not the whole cost base.

The rest of the series

Not on the overview because five charts is as much as one decision needs — but here in full, on one period switch. Each bar sums the four quarters ending there — a full year, brought up to today.

Total Revenue

$6.13BQ2 2026-0.6%

1Y: -2.45%2Y: -3.45%5Y: -3.16%

Everything the company sold, before any costs. Each bar sums the four quarters ending there — a full year, brought up to today.

Profit

$209MQ2 2026-15.0%3.4% of revenue

1Y: -70.14%2Y: -79.10%5Y: -88.00%

What was left after every cost, including tax. Each bar sums the four quarters ending there — a full year, brought up to today.

Profit margin

3.4%Q2 2026-14.5%

How much of every dollar of sales the company keeps as profit. A grocer keeps a few cents; a software company can keep half. Each point covers the four quarters ending there — a full year, brought up to today.

Free Cash Flow

$567MQ2 2026-17.0%

1Y: -13.83%2Y: -33.61%5Y: -75.18%

Cash left over after running and maintaining the business. Each bar sums the four quarters ending there — a full year, brought up to today.

Profit per share

$0.78Q2 2026-17.0%

1Y: -70.90%2Y: -79.95%5Y: -88.65%

The same profit, split across every share. If this lags the profit chart above, the company is issuing shares and your slice is getting smaller. Restated onto today’s share count, so stock splits do not show as jumps. Each bar sums the four quarters ending there — a full year, brought up to today.

Shares outstanding

263.81MQ2 2026+1.0%

How many shares the profit is divided across. Rising is dilution; falling is the company buying itself back. Restated onto today’s basis, so splits do not show as jumps. Each point covers the four quarters ending there — a full year, brought up to today.

Price to earnings

14.3xQ2 2026+81.3%

14.3x today · median 4.7x and range 2.9x–14.3x across the points shown, Q3 2021 to Q2 2026

Paid per unit of yearly profit. Periods with a loss, or profits too small for the ratio to mean anything, are left out — the line breaks rather than drawing through them. Each point covers the four quarters ending there — a full year, brought up to today.

Dividends paid

$18MQ2 2026-18.2%

1Y: -92.14%2Y: -93.92%

Cash handed to shareholders. A flat line at zero means the company pays none. Each bar sums the four quarters ending there — a full year, brought up to today.

About Organon & Co.

Ticker: OGN
SEC classification: Pharmaceutical Preparations (2834)
Listed on: NYSE
Financial year ends: December 31
Filer size: Large accelerated filer

About this data

Everything above comes from Organon & Co.’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted.

Not reported by this filer: Total Operating Expenses, Operating Income, Interest Income, Net Interest Income, Non-interest Income, Non-interest Expense, Provision for Credit Losses, Deposits, Loans, Short-term Investments, Short-term Borrowings, Borrowings (total), Finance Lease (current), Finance Lease Liabilities (total), Finance Lease (noncurrent), and Share Repurchases. Companies choose which XBRL tags to use, and anything untagged cannot be recovered — so these are blank rather than guessed.